We are live on ! Find out more
PCSA icon

Processa Pharmaceuticals
PCSA

13 hedge funds and large institutions have $342K invested in Processa Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more capital invested

Capital invested by funds: $75.9K → $342K (+$266K)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

18% more funds holding

Funds holding: 11 → 13 (+2)

0.02% more ownership

Funds ownership: 0.13% → 0.14% (+0.02%)

Holders
13
Holders Change
+2
Holders Change %
+18.18%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$218K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$55.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$53.4K
4
TSS
Two Sigma Securities
New York
+$7.66K
5
Citigroup
Citigroup
New York
+$7.19K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$13.5K
2
UBS Group
UBS Group
Switzerland
-$13.2K
3
AGM
Alpine Global Management
New York
-$10.9K
4
CSS
Cubist Systematic Strategies
Connecticut
-$8.58K
5
Jane Street
Jane Street
New York
-$3.95K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$198K +$218K +41,208 New
Geode Capital Management
2
Geode Capital Management
Massachusetts
$58.2K +$53.4K +10,109 +500%
Vanguard Group
3
Vanguard Group
Pennsylvania
$55.3K +$55.7K +10,551 +1,080%
VF
4
Virtu Financial
New York
$8K -$13.5K -2,555 -61%
TSS
5
Two Sigma Securities
New York
$6.96K +$7.66K +1,450 New
Citigroup
6
Citigroup
New York
$6.53K +$7.19K +1,362 New
SG
7
StoneX Group
New York
$3.64K +$4K +758 New
SCA
8
Sassicaia Capital Advisers
New York
$3.07K +$3.37K +639 New
MMA
9
Miracle Mile Advisors
California
$1.92K +$2.11K +400 New
TRCT
10
Tower Research Capital (TRC)
New York
$459 -$11 -2 -2%
Bank of America
11
Bank of America
North Carolina
$72 +$58 +11 +275%
Jones Financial Companies
12
Jones Financial Companies
Missouri
$40 +$42 +8 New
Wells Fargo
13
Wells Fargo
California
$30 – – –
UBS Group
14
UBS Group
Switzerland
– -$13.2K -2,584 Closed
AGM
15
Alpine Global Management
New York
– -$10.9K -2,137 Closed
CSS
16
Cubist Systematic Strategies
Connecticut
– -$8.58K -1,674 Closed
Jane Street
17
Jane Street
New York
– -$3.95K -771 Closed
SFA
18
Sequoia Financial Advisors
Ohio
– -$2.25K -440 Closed
SS
19
SBI Securities
Japan
– -$2 – –

PCSA Hedge Fund Activity: Q3 2025 in Review

13 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q3 2025, worth a combined $342K — up 350% from $75.9K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PCSA positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $218K. The largest seller was Virtu Financial, cutting an estimated $13.5K.

  • 13 institutional investors held Processa Pharmaceuticals (PCSA) as of Q3 2025, up from 11 in Q2 2025.
  • Funds reported $342K of Processa Pharmaceuticals stock for Q3 2025, up 350% quarter-over-quarter.
  • 7 funds opened new Processa Pharmaceuticals positions in Q3 2025 and 5 closed out, a net change of +2 holders.
  • The largest Processa Pharmaceuticals buyer in Q3 2025 was Stonepine Capital Management, an estimated $218K added.
  • The largest Processa Pharmaceuticals seller in Q3 2025 was Virtu Financial, an estimated $13.5K sold.

Based on aggregated 13F filings for Q3 2025.